There is great interest in characterizing the genetic architecture underlying drug response. For many drugs, gene-based dosing models explain a considerable amount of the overall variation in treatment outcome. As such, prescription drug labels are increasingly being modified to contain pharmacogenetic information. Genetic data must, however, be interpreted within the context of relevant clinical covariates. Even the most predictive models improve with the addition of data related to biogeographical ancestry. The current review explores analytical strategies that leverage population structure to more fully characterize genetic determinants of outcome in large clinical practice-based cohorts. The success of this approach will depend upon several key factors: (1) the availability of outcome data from groups of admixed individuals (that is, populations recombined over multiple generations), (2) a measurable difference in treatment outcome (that is, efficacy and toxicity end points), and (3) a measurable difference in allele frequency between the ancestral populations.
Introduction
Many genes underlying drug response remain largely uncharacterized. Single-nucleotide polymorphisms (SNPs) are the marker of choice for studying genes related to such complex traits because they are abundant, stable across generations and informative for linkage disequilibrium mapping when selected for appropriate allele frequencies. [1] [2] Currently, there are more than 12 million SNPs deposited in GenBank, 6.5 million of which have been validated (http:// www.ncbi.nih.gov/SNP). Single nucleotide polymorphisms occurring every 100-300 bases along the genome capture approximately 80% of the total genetic diversity in humans, 3 whereas copy-number variation, the most prevalent type of structural variation in the human genome, contributes to much of the remaining 20%. 4 These and other forms of genetic variation within individuals and between individuals contribute to variability in treatment response in the context of relevant environmental factors.
database is an important resource in the selection of markers for the characterization of complex traits such as drug outcome. [9] [10] Rare variants can also contribute to variability within complex traits. 11 Through the use of next-generation sequencing technologies, the 1000 Genomes Project is expected to identify over 95% of all variants with allele frequencies greater than 1% within 11 geographically diverse populations. The importance of world-wide sequencing efforts such as these cannot be overstated. Many rare variants have occurred in recent human history, and they therefore tend to have greater population diversity than common variants. 12 Such variants are ideal for admixture mapping.
Mining biobanks for admixture mapping
Admixture, a common form of gene flow between populations, refers to the process whereby two or more genetically and phenotypically diverse populations begin to mate and form a new, mixed or 'hybrid' population. [13] [14] Each chromosome of an admixed individual resembles a mosaic of chromosomal segments derived from a particular ancestral population ( Figure 1 ). The use of such populations to map genes was proposed over 50 years ago, 15 but has come into prominence recently due to the availability of genomewide sets of highly informative markers and adequate statistical tools to successfully conduct these studies. [16] [17] [18] [19] Markers with different frequency distributions among ancestral populations can be used to adjust for population stratification among admixed populations. Such markers are often referred to as ancestry informative markers (AIMs) because they can distinguish the ancestral origin of the haplotype on which they reside. If an ancestral population carries a genetic risk allele at a higher frequency than other(s), then genomes of affected 'mixed-ancestry' offspring will share a greater level of ancestry (DNA) from that population around that disease susceptibility locus, compared with the background ancestry level in the genomewide average or compared with the ancestry sharing among discordant individuals around the same location. 20 Populations like African Americans, African Caribbeans and Mexican Americans were formed within the past 400 years (that is, within approximately 15 generations). 21 Stretches of DNA with contiguous European and African ancestry have therefore not had sufficient time to break up due to recombination; hence, allelic associations in these populations typically extend over distances as large as 20-30 cM. [22] [23] For studies mapping genes contributing to variability in drug outcome within these populations, the large amount of LD (that is, linkage between markers with ancestral information) in these admixed populations will translate into smaller requirements for both marker saturation and sample size. 19, [24] [25] This principle is important because it is estimated that about 20% of the genetic material in today's African-American population originated from a non-African, predominantly Caucasian, source. 26 Gene mapping can be accomplished within admixed populations through the application of three fundamental steps. First, a panel of AIMs that differentiate well between ancestral populations must be designed. Next, individuals are genotyped using the panel (for example, following casecontrol design), and the mosaic of ancestries is inferred for each individual. Finally, the inferred ancestral profiles are scanned in search of an aberration skewed toward the ancestral population with the higher risk, as expected based upon prior association with the locus of interest. Given the recent and common origin of all human populations, any two unrelated individuals share more than 99.8% of their DNA sequence, and variation within populations is by far greater than variation between populations. 27 The admixture between geographically isolated populations such as Europeans, Africans and Native Americans, has only a small average effect (0.2%) on the genetic variation of the gene pool. For most genomic regions, the parental populations have similar allele frequencies and, at these frequencies, admixture may be of limited consequence. 28 However, at other loci, there have been marked changes in allele frequency in the time because the separation of parental populations, and it is at these loci that difference in frequencies of risk alleles can be leveraged to identify the loci impacting clinically recognizable traits. 9, [29] [30] [31] In other words, admixture mapping is most applicable when variability in a given drug outcome is significantly different between the ancestral populations from which the admixed population has been formed. When such a trait is studied, admixed individuals demonstrating greater variability are expected to show an elevated genomic contribution from the ancestral population with the higher prevalence of the trait around the associated genetic loci.
The arguments in favor of admixture mapping are compelling, and the statistical methods are improving The two ancestral population, 1 and 2, are represented by blue and red chromosomes, respectively. Individuals in the subsequent generation may or may not receive an intact chromosome 1 or 2 from their ancestor. As generations continue, mosaics develop for chromosomes 1 and 2 as a result of recombination at meiosis. The admixed individual's genomes are a mosaic of the two initial ancestral chromosomes.
rapidly. Until recently, the availability of admixed populations suitable for study (with differences in disease and/or allele frequencies) has been limited. 18, 32 Most pharmacogenetic association studies conducted to date have involved retrospective genotyping of archived DNA from previous randomized treatment trials. 33 Nearly a decade ago, international efforts were initiated to launch the construction of DNA biobanks that were either based in the community (population based) or in the context of routine clinical care (practice based). 34 Biobanks typically include biological samples (that is, serum, plasma and DNA) linked to structured clinical databases (that is, comprehensive electronic medical records). These biobanks are uniquely suited for studies quantifying the impact of ancestry in admixed population and have a role in the pathway to personalized medicine in which treatments will be no longer be 'one size fits all' but instead 'tailored' to the molecular and genetic profiles of each patient based on pharmacogenetic predictors. For example, the eMERGE network (electronic Medical Records and Genomics) represents a group of five large academic medical institutions within the United States that have collected DNA linked to secure encrypted clinical data extracted from dense electronic medical records. 33 The participating institutions, Vanderbilt University (coordinating center), Northwestern University, Marshfield Clinic, Mayo Clinic and Group Health, have begun the process of standardizing clinical phenotypes within the context of disease (onset and progression), and treatment outcome (efficacy and toxicity), for ongoing genome-wide association studies using densely populated high-throughput SNP scans (http://www.gwas.net). In many cases, these data are available along with self-reported race and family structure across multiple generations. Similar efforts are also underway at Harvard Pilgrim and Fallon Healthcare (in the Northeastern United States); Kaiser Permanente Georgia (in the Southeastern United States); HealthPartners, Henry Ford and Marshfield Clinic (in the Midwestern United States); and Kaiser Permanente Colorado, Kaiser Permanente Northwest, Group Health Cooperative, Lovelace, Kaiser Permanente Southern California, Kaiser Permanente Northern California and Kaiser Permanente Hawaii (in the Western United States). In some cases, race-specific biobanks are also being developed. The African-American DNA biobank at Howard University in Washington, D.C. represents the largest resource of its kind. 35 The missing ancestry in current biobanks Most biobanks collect only limited historical information on the ancestry (origin) of the donors. In the United States, it would be inaccurate to assume homogeneity of population ancestry in the context of clinical practice-based biobanks. Most often race/ethnicity ancestry data are missing from the electronic medical records; in some cases, race/ethnicity is estimated by a study coordinator's visual inspection at time of enrollment; in others, study participants are asked directly to self-identify a single race/ ethnicity that they feel best identifies them. Although selfreported race and ancestry can predict general ancestral clusters, self-reported race does not reveal the extent of admixture. Furthermore, group identity (for example, the Hispanic-American identity often indicated in queries of ethnicity) can be much more complex than self-identity, and it is therefore even less feasible to rigorously define an ethnic group by its genome.
Hence, there is 'missing ancestry' in these biobank resources. Currently, two main approaches are used for inferring genetic ancestry. If the ancestral populations of the cohort being studied are known, AIMs can be genotyped to infer global ancestry using principle components analysis (PCA) or other clustering algorithms. [36] [37] [38] Often, however, the ancestral population information is usually not available or not known with confidence. This is particularly true for populations of relatively complicated admixture or unknown origins. In these cohorts, a large number of loci need to be genotyped, followed by the application of PCA to individual-level genetic data, to fully characterize biogeographical ancestry. Adjustment made through this approach increases investigator confidence that pharmacogenetic findings are not spurious associations.
In the hypothetical example shown in Figure 2 , the presence or absence of toxicity could be adjusted using a dummy variable in an admixed population with parental (ancestral) populations A1 and A2. Any allele showing higher frequency in the A1 population than in A2 could in theory show association with toxicity. Thus, the stratification variable would be a confounding variable, associated with both the exposure (alleles, haplotypes or genotypes) and the outcome of interest (higher incidence of toxicity in the A1 population than in the A2). This problem is compounded when analyses are conducted on a genomewide scale. The extrapolation of pharmacogenomic data from genetically homogeneous populations to admixed populations would be expected to generate large numbers of false-positive and false-negative results. The failure to recognize admixture can thus prevent proper characterization of the genetic structure underlying adverse drug reactions in populations such as these, leading to inaccurate prediction of outcome and incorrect inferences about the evolutionary factors driving patterns of diversity. 39 Consequently, an in silico method of data mining is needed to extract and use non-redundant AIMs from the everincreasing wealth of genomic data in public domains. 40 Currently, the amount of information characterizing variants across the human genome is limited for the majority of racial and ethnic groups. 10, 41 Nonetheless, use of these data represents an economical, rapid, and practical strategy for developing a comprehensive and informative panel of AIMs. 28 
Selection of AIMs
Admixture-based methods rely on the use of suitable markers, and accurate estimation of allele frequencies, from appropriately identified parental populations. 42 Theoretically, any marker that has large allele frequency difference between ancestral populations can be used for estimating individual ancestry and for admixture mapping. These include SNPs, restriction fragment length polymorphisms, microsatellites/simple tandem repeats, insertion/deletion polymorphisms and copy number variations. 4, [43] [44] [45] [46] [47] The ideal AIM has one allele that is monomorphic in one population (P ¼ 1.0) and that is not present in another. 48 However, most alleles are shared between populations, and alleles common in one population are often common in other populations. As most genetic markers are unaffected by admixture, it is imperative to identify and choose the most informative markers that show high levels of absolute difference in allele frequency between the parental populations. 30 To date, several measures of marker informativeness (ability of markers to differentiate between populations) have been developed to select the most informative AIMs 48 from an ever-increasing wealth of genomic databases. [49] [50] [51] [52] These measures include: absolute allele frequency differences (d), Shannon information content, Fisher information content, measure of informativeness for assignment (I n ) and F-statistics index (F ST ). The cutoff values for d are highly subjective, and have steadily decreased over time from 0.5 43 to 0.4 44 With so many methods available, it is important to understand their similarities and differences in practice. Each approach applies a different computer algorithm for marker selection. For example, measures such as d can be used for only two ancestral populations at a time, 48 whereas measures such as F ST , Fisher information content and Shannon information content can be applied to select informative markers for admixed populations formed from two or more ancestral populations. Furthermore, the estimation of Fisher information content, I n and Shannon information content requires known parental proportional contributions to the admixture. Some analytical methods require this degree of granularity whereas others do not. If a study is properly designed, the AIM selection method can often lead to reductions in the amount of genotyping required for inference.
Several SNP panels have been used to adjust the results of genetic association studies according to population admixture over the past few years 21 47 However, it is likely that different sets of markers will be needed for different populations. 20 
Admixture proportion estimation methods
Understanding the genetic consequences of admixture in large populations is important because admixture can be both a confounding factor and a source of statistical power. 56 Admixture is a distinct disadvantage within some analytical contexts. Admixture causes false-positive associations in genetic studies, subjecting case-control findings to stratification bias. Population stratification occurs when the population under study is assumed to be homogeneous with respect to allele frequencies but in fact is comprised of subpopulations that have different allelic frequencies for a particular gene of interest. If these subpopulations also have differing frequencies for the primary trait of interest, then subpopulation membership is a confounder. 57 As such, an association between a gene and drug outcome may be incorrectly estimated without properly accounting for population structure, 29 leading to both false-positive and false-negative associations. 58 For the bias due to population structure to exist, both of the following conditions must be true: (a) the frequency of the marker of interest varies significantly by race/ethnicity, and (b) the background prevalence of the trait varies significantly by race/ethnicity. 59 Currently, three fundamentally different methods are used to correct for confounding induced by admixture within association studies. 37, 39, 60 These methods are (1) genomic control, (2) structured association and (3) principle component analysis. Genomic control uses a set of noncandidate, unlinked loci to estimate an inflation factor, l, which was caused by the population structure present and then corrects the standard w 2 test statistic for this inflation factor. The structured association method uses Bayesian techniques to assign individuals to 'clusters' or subpopulation classes using information from a set of noncandidate, unlinked loci and then tests for an association within each 'cluster' or subpopulation class. As noted earlier, PCA can also be used to identify and adjust for population substructure due to admixture. 37 In PCA, genotype data are used to infer axes of genetic variation and determine principal component scores, which are then included as covariates in the analysis model. Thus, PCA collectively scores a set of alleles, allele frequencies for which are correlated because they derive from the same parental population.
In other situations, however, admixture may be an advantage for pharmacogenomic research. Ancestry-phenotype correlation studies are useful for examining the role of genetic factors underlying observed racial/ethnic differences in loci influencing complex phenotypes, such as drug response. For example, population admixture results in longer LD segments than in the previously isolated populations, enabling fewer genetic markers to be used in association studies. 23 This property is valuable in investigating causality. 61 and is thus highly useful in pharmacogenomic research. Admixed populations in clinical practice-based cohorts can also be used to gain additional information on people, such as African groups, which are typically underrepresented in clinical drug trials. Studies in African-American populations in particular will fill important pharmacogenomic information gaps. Estimation of the genetic admixture proportion in the admixed population can be performed at the population level using allele frequencies or at the individual level using genotype frequencies. 13, [62] [63] In the former case, the focus is on estimating the fraction of genes in the admixed population that come from each parental population. In the latter, the proportion of loci in the genome of a single individual that come from a parental population is used to adjust for admixture fractions in association studies. 64 As shown in Table 1 , two types of approaches are typically used to estimate admixture: Bayesian methods and assignment of maximum likelihood. 18, 65 Both approaches examine the transmission of alleles according to parental population (for example, African versus European by descent) at specific loci along each chromosome. 66 Programs such as AdmixMap, AncestryMap and STRUCTURE leverage data from the founding populations (for example, in the form of individuals for STRUCTURE), to provide an informative prior probability and calculate the posterior distribution of admixture estimates using a Markov Chain Monte Carlo method within the Bayesian framework. 39, [67] [68] [69] [70] Conversely, ML estimation methods, such as individual biogeographical ancestry, population stratification inference via MIXture model and frequentist estimation of individual ancestry proportion, fall under the frequentist framework, where earlier information is not required. 54, [71] [72] Application to clinical data Although genome-wide association studies are being conducted on an unprecedented scale in cohorts that are disease based, most of the work conducted in the context of treatment outcome has been limited to biological candidate genes. 73 The application of genome-wide SNP-scanning platforms to studies of drug response has occurred only recently, and the number of such studies in the literature remains relatively small. As several genome-wide association studies have recently been reported for outcomes related to lipid-lowering therapy, [74] [75] [76] the following discussion/example explores the need for analytical strategies that deal with admixture specifically within in the context of cardiovascular risk reduction.
Cardiovascular disease is responsible for one in every three deaths in the United States, and it affects patients of all races and ethnicities. 77 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins) are highly efficacious in the primary and secondary prevention of cardiovascular disease in patients at risk. 78 The efficacy of these drugs is directly proportional to the amount by which they decrease lowdensity lipoprotein cholesterol. 79 Statins are currently the most widely prescribed class of medications in the world, and the last decade has seen a trend toward much more aggressive dosing. 80 In Treating to New Targets, a randomized treatment trial of more than 10 000 subjects with known coronary artery disease, high-dose atorvastatin was clinically superior to low-dose atorvastatin. 81 However, when 1984 rigorously selected participants from this trial recently underwent whole genome scanning (322 000 SNP scan from Perlegen), no variants from this scan were associated with low-density lipoprotein cholesterol reduction at a level that reached genome-wide significance. .
Mapping genes that predict treatment outcome

TM Baye and RA Wilke
Although subsequent efforts reflecting combined cohorts from multiple statin treatment trials (Treating to New Targets, atorvastatin 10 mg daily; cholesterol and pharmacogenomics, simvastatin 40 mg daily; and pravastatin/ inflammation CRP evaluation, pravastatin 40 mg daily) are beginning to identify variants associated with lipid lowering efficacy, their effect size seems to be relatively small. 82 This may in part be due to misclassification bias introduced by using single-dose efficacy. The source of this bias can be explained as follows.
Individual trials such as those introduced above typically have lipid data available for only a single-treatment dose. However, if genome-wide association studies are to resolve genetic determinants of outcome for these drugs, a more thorough characterization of phenotype may be necessary.
To reduce misclassification, data should be collected across multiple doses, and full dose-response relationships should be leveraged to extract rigorous phenotypic traits representing potency (ED 50 , dose causing half maximal effect) and maximal efficacy (E max ). 73 Such an approach is possible within the context of clinical practice-based data sets. 33, 35 Biobanks such as those contained within the National Institutes of Health-funded eMERGE Network (http:// www.gwas.net) represent an unprecedented opportunity to characterize treatment outcome across large academic medical centers with DNA samples linked to secure encrypted copies of comprehensive electronic medical records. Genome-wide association studies are already being conducted within these combined biobanks for six primary study outcomes (including modifiable cardiovascular risk factors).
Data sets such as these are typically comprised of individuals with large variability in ancestry. Thus, analytical strategies adjusting for admixture will further improve resolution of the genetic architecture underlying lab-based efficacy for drugs used to reduce cardiovascular risk. With the statistical power that accompanies these large multiinstitutional networks, investigative teams will also be able to characterize the impact of admixture on cardiovascular efficacy (that is, the ability of pharmacologic intervention to reduce hard cardiovascular events). Figure 3 shows the distribution of death from acute myocardial infarction across the United States. Although disparities in cardiovascular death rate clearly reflect complex interactions between cultural factors (for example, systems of care) and operational factors (for example, access to care), the contribution made by genetic factors is substantial. Robust admixturemapping strategies will therefore be essential to the successful characterization of genetic determinants of treatment outcome within this context.
Admixture in pharmacogenomics
The pharmacologic treatment of cardiovascular disease involves optimization of hemostasis, hemodynamics and lipid homeostasis (Table 2) . Antiplatelet agents are a mainstay of therapy. Although aspirin is efficacious in the secondary prevention of coronary artery disease, there is wide variability in the degree to which this drug attenuates platelet aggregation. [83] [84] [85] Aspirin-induced changes in platelet function are heritable, 85 and the genetic architecture underlying aspirin response has therefore been an intense focus of investigation. 83, [86] [87] Clopidogrel is used to prevent stent restenosis after percutaneous intervention, and candidate genes contributing to its efficacy are rapidly coming into view. [88] [89] [90] Pharmacologic modulation of clotting factor synthesis is highly efficacious in the prevention and treatment thromboembolic disease, and rigorous gene-based Mapping genes that predict treatment outcome TM Baye and RA Wilke dosing models (including VKORC1, CYP2C9 and CYP4F2) are being developed for warfarin therapy (based on age, gender, ancestry and a variety of clinical covariates; http:// www.warfarindosing.org). These models will be stronger when the data are corrected for admixture. 91 For example, CYP2C9 inactivates S-warfarin and the distribution of variant CYP2C9 alleles is influenced by ancestry. The defective CYP2C9 * 5 allele, previously found in AfricanAmericans and sub-Saharan Africans, but not in Europeans and their descendants, has been recently detected in a white Brazilian man. The relative contributions of European-, African-and Native Americans to his genetic pool were 92.0, 7.5 and 0.5%, respectively. [92] [93] The CYP2C9 * 5 allele was also detected in the proband's mother and in one of his brothers, consistent with inheritance through matrilineal African ancestry. 92 Thus, although the contribution of African alleles to his genome was limited to 7.5%, this relatively small contribution will be critical in predicting his response to medications.
The genetic underpinning of outcome-related antihypertensive therapy has also been an intense focus of investigation over the past decade. First-line agents recommended by the Joint National Commission on Hypertension (JNC-VII) include b-blockers and thiazide diuretics. Similar to warfarin, variance in outcome related to b-blocker use can be partly explained by a combination of well-characterized pharmacodynamic and pharmacokinetic candidate genes (ADRB1, ADRB2, CYP2D6 and UGT1A1). [94] [95] However, current models are limited 96 in part due to the impact of race. 97 Factors contributing to the efficacy of thiazide diuretics is also influenced by ancestry, and some have been partly characterized (for example, polymorphisms in the G-protein b 3 -subunit). [98] [99] As noted earlier, lipid-lowering therapy is also a pivotal component in the overall prevention and treatment of cardiovascular disease, and earlier work with biological candidate genes has clearly demonstrated that both pharmacodynamic and pharmacokinetic markers are associated with the degree to which statins lower low-density lipoprotein cholesterol (HMGCR, CYP3A4 and CYP3A5, respectively). [100] [101] [102] In 2005, we reported that variability in CYP3A5 was associated with the severity of statin-related muscle toxicity, 103 and distribution of the causative allele (CYP3A5*3) is strongly influenced by ancestry. The CYP3A family of enzymes catalyze the oxidative Phase-I metabolism of nearly half of all known therapeutic agents. 104 Interindividual variability in CYP3A activity exceeds 80%, 105 and major interethnic differences in the pharmacokinetics of some CYP3A substrates have been reported. 106 Allele frequency differences for representative variants in CYP3A4 and CYP3A5 are shown in Table 2 . Across the pharmacogenetic functional variant(s) investigated, allele frequencies within the admixed African-American population are intermediate between the respective ancestral (European and African) populations, confirming our initial hypothesis that admixed populations require a different drug evaluation strategy than the relatively homogenous ancestral populations.
Expanding the model
It is important to recognize that variability in CYPdependent drug oxidation only represents a single component of an individual's genetically predetermined capacity for drug disposition. 103 For example, many statins (and CYP-derived hydroxyl-statin intermediates) undergo additional modification through Phase-II conjugation. Promoter SNPs in UGT1A1 are associated with Gilbert's disease, and some predict outcome in the context of cancer drugs. 94 Recent data indicate that UGT1A3 variants impact statin kinetics. 107 Membrane transporters are also known to influence statin kinetics. Genetic variability in the organic anion transporter (solute carrier) SLCO1B1 (solute carrier organic anion transporter family, member 1Bi) has been associated with differential modulation of the cellular transport of statins into a variety of tissues, making it very tempting to speculate that SLCO1B1 genotype might influence subject risk for the development of statin-related outcomes. To date, one of the most noteworthy successes of the application of genome-wide SNP scanning to the characterization of drug outcome has been the identification of SLCO1B1 variants associated with statin-induced myopathy. 74 In this effort, the SEARCH collaborative group applied a 317 000 SNP scan (Affymetrix) to combined cases of definite myopathy (serum creatine kinase, CK 410-fold upper limit of normal) and 'incipient' myopathy (CK 4three-fold upper limit of normal). A single variant survived statistical correction for multiple testing. After re-sequencing studies revealed that this variant was in LD with a previously characterized nonsynonymous coding variant (V174A) in SLCO1B1, the putative causative allele was further tested for association in a subset of 49 definite myopathy cases from the original study population, revealing an odds ratio for myopathy of 4.5 per copy of the C allele (95% confidence interval: 2.6-7.7), in patients exposed to high-dose simvastatin (80 mg daily). Replication efforts conducted in the Heart Protection Study (HPS) cohort, using data from trial participants exposed to a lower dose of simvastatin (40 mg daily) revealed a more modest risk, risk ration ¼ 2.6 (95% confidence interval: 1.3-5.0). 74 Efforts are now underway to quantify the effect of this variant on myopathy risk in a clinical practice-based setting (www.pharmgkb.org). Similar to other efforts being conducted within the world's growing biobanks, success will depend upon a thorough consideration of admixture (Figure 4) .
Limitation of admixture estimation methods
There is a range of possible scenarios by which admixture dynamics could impact outcome. Two extreme cases occur when (1) parental populations contribute to the hybrid in a unique generation of admixture (that is, an intermixture or hybrid-isolation model); and (2) there is continuous geneflow across several generations from the ancestral populations to the admixed one (that is, a continuous gene-flow model). In real life, however, it should be emphasized that virtually no admixed human population exhibits single time or discrete admixing (that is, hybrid-isolation model) of the type that can be artificially produced with inbred strains of model organisms. Rather, human admixing is continuous over time-a phenomenon that creates variation in the degrees of admixture possessed by any one individual in an admixed population. This variation can be large and raises issues in the analysis of admixed populations, as it will create patterns of LD that are complicated and difficult to interpret in simple association studies. 108 Current population genetic models and software are often limited to the island model or continuous gene flow, neither of which is likely to accurately represent the complexity of the process by which the majority of admixed human or nonhuman populations are formed. 109 Even in the data-rich field of modern genomics, no amount of data can make up for an inappropriate model. 110 Gender Many complex traits with a large impact on public health are sexually dimorphic, for example, high-density lipoprotein cholesterol. Males or females may contribute disproportionate amounts of admixture or in some cases admixture may be restricted to one gender only. 111 Unequal contributions of the different genders of an ancestral population to an admixed population result in a phenomenon known as 'gender-biased admixture'. Differential susceptibility to a disease in males and females is a common observation in human populations (a case of parent of origin effect). [112] [113] Whether gender-biased admixture influences treatment outcome (that is, ability of pharmacological intervention to increase circulating high-density lipoprotein cholesterol level) remains to be determined. 35 Gender-biased admixture will cause admixture estimates from loci with different patterns of inheritance to differ markedly. Thus, admixture estimates are not pooled from all loci, but are compared between loci with different patterns of inheritance. As a result, if females contribute more than males to a given trait within an admixed population, estimates of admixture will lie on a gradient: mitochondrial DNA 4 X-chromosome 4 autosome 4 Y-chromosome. By contrast if males contribute a greater proportion, the gradient is reversed: Y-chromosome 4 autosome 4 X-chromosome 4 mitochondrial DNA. 110 Gender-biased gene flow with elevated European male and African female contributions 44, [114] [115] [116] to AfricanAmericans, as a result of the European explorers, traders and missionaries who have traveled the world over the past 500 years have been predominantly males, results an admixed populations likely to exhibit male-biased admixture. 110 A gender-biased pattern of gene flow with an excess of European male and African female ancestry was also shown recently where the African-American X-chromosome showed consistently elevated levels of African ancestry compared with the autosomal regions variability in African ancestry. 117 Due to a three-fold higher European male contribution compared with European females to the genomes of African-American individuals (Y-chromosome versus mitochondrial DNA), admixture-based gene discovery will have the most power for the autosomes and will be more limited for X-chromosome analysis. 118 This principle has been illustrated above for warfarin outcomes in the context of an autosomal variant, CYP2C9*5, transmitted through materilinear African ancestry. 92 Furthermore, any genome scan aimed at identifying variants that predict treatment response on the X-chromosome in AfricanAmericans should account for its lower admixture fraction. 67, 69 The current admixture approach considers that all neutrally evolving loci should thus give the same estimate of admixture proportions resulting from gender-biased admixture estimates. 117 
Race
The term race (often used to imply geographic or genetic ancestry) reflects population clusters based on genetic differences due to evolutionary pressure. These differences could indicate variation in allele frequencies and/or patterns of polymorphism. Inter-racial variations in response to medication were observed nearly a century ago. In 1920, Paskind 119 investigated the effect of atropine sulfate on 20 Caucasians and 20 African-American men in Cook County Hospital, Chicago, IL, USA. Initial slowing of the heart rate, reaching a maximum of 10-15 min, was observed frequently in European-American but not in African-American subjects. More recently, self-reported race has been leveraged to direct specific therapies impacting other hemodynamic parameters (both physiological and pathophysiological). The combination of hydralazine and isosorbide dinitrate has clearly been associated with greater clinical benefit in patients of specific races, within the context of congestive heart failure. [120] [121] Although prescribing on the basis of selfreported race remains controversial, targeted application of such an approach has been driven by well-designed Figure 4 Proposed model to integrate DNA biobanks (for example, phenotypic data and genotypic data) with ancestry informative markers (AIMs) to adjust population structure and/or map genes in practicebased pharamcogenetic/genomic studies.
trials wherein self-reported black patients randomized to hydralazine and isosorbide dinitrate realized a 43% reduction in mortality compared with standard therapy (95% confidence interval: 11-63%).
120
Multiple ancestry-dependent associations and disease susceptibility loci have been reported in African-Americans specifically, using admixture mapping for cardiovascular disease [122] [123] dysmetabolic traits [124] [125] and cancer. 66 The success of each effort was partly due to marked differences in the frequency of each respective trait in ancestral populations. However, none of these studies has led to finely mapped genes. Thus admixture mapping is an intellectually appealing concept, but stringent criteria have yet to be achieved, 31 and independent replication is pending for these reports. Recently, Reich et al. 126 mapped a clinically relevant immune response trait and replicated this association in an independent sample on chromosome-1, demonstrating that admixture mapping can not only coarsely localize traits but can also fine-map a phenotypically important variant.
Ethnicity
Ethnicity is defined by commonality in culture and social practices, including diet. 127 Examining allele frequencies in different ethnic groups can help differentiate functional polymorphisms (that is, those causing a change in phenotype) from marker polymorphisms (that is, those in LD with functional polymorphisms in a selected subset of individuals). As the LD of a marker polymorphism is unlikely to remain true across the breadth of human diversity, identifying the correct, causative polymorphism is important for designing accurate genetic tests for people of all ethnic backgrounds.
Historically, the North American population was formed by episodic migration flows and admixture thereafter. Although the majority of these flows initiated from mainly Europe, America's current demographic makeup is much more diversified. In 2008, the US Census Bureau (www. census.gov/popest/estimates.php) estimated the national population to be 304.3 million. Of this total, 15.4% selfidentified as being of Hispanic or Latino origin, 12.8% as African-Americans and 4.4% as Asians. This heterogeneity can be easily observed in health risk factors to disease prevalence. Admixture among these population groups continues to be an ongoing process, and the country is becoming a multi-racial genomic mosaic country. It is time to develop and standardize treatment and drug-testing procedures for this admixed population. Interethnic differences in drug responses are a well-recognized problem resulting in both undertreatment and overtreatment of individuals receiving similar doses of drugs, with the potential for lack of therapeutic effect and toxicity. The recent reporting of significant pharmacogenetic differences in b 2 -adrenergic receptor polymorphisms and bronchodilator responses to albuterol between the two largest Latino admixed groups, namely Mexicans and Puerto Ricans, 93 is a striking example of the hazards that are associated with ignoring admixture within ethnic groups, as is often done in the pharmacogenetic literature.
Conclusion
The genetic architecture underlying treatment response remains largely uncharacterized for most prescribed drugs. As candidate gene and genome-wide approaches are increasingly being applied to archived biological materials from existing clinical trial databases, the world's growing practicebased biobanks will represent a powerful resource for characterizing the generalizability of these findings within the community. These databases contain large numbers of individuals with admixed ancestry. In the United States, there has been a significant intermixing among racial/ ethnic groups, thereby creating populations that are a mosaic of multiple continental ancestral populations (European-, African-and Native American). This admixture creates long segments of DNA (haplotypes) that have distinguishable ancestral origins, and, hence, genetic differences in the prevalence of polymorphisms affecting drugmetabolizing enzymes, drug transporters, receptors and signal transduction mechanisms must be considered when individualizing pharmacotherapy. Failure to adequately control population stratification due to ancestry may lead to spurious results in large-scale pharmacogenomic association studies.
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